# Plus Therapeutics

> biopharmaceutical company

**Wikidata**: [Q113510380](https://www.wikidata.org/wiki/Q113510380)  
**Source**: https://4ort.xyz/entity/plus-therapeutics

## Summary
Plus Therapeutics is a publicly traded biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. Founded in 1996 and headquartered in Austin, Texas, it is listed on the Nasdaq stock exchange under the ticker symbol **PSTV**. The company specializes in advancing innovative treatments through clinical-stage research and development.

## Key Facts
- **Legal Name**: Plus Therapeutics, Inc.
- **Website**: [plustherapeutics.com](https://plustherapeutics.com/) (English-language)
- **Inception**: 1996
- **Entity Type**: Public company (instance of a publicly traded corporation)
- **Headquarters Location**: Austin, Texas, United States
- **Primary Field of Work**: Targeted therapy, with a focus on oncology and rare diseases
- **Stock Exchange Listing**:
  - **Exchange**: Nasdaq
  - **Ticker Symbol**: PSTV
  - **Central Index Key (CIK)**: 0001095981
  - **Listing Start Year**: 2000
- **Crunchbase Organization ID**: cytori-therapeutics
- **Wikidata Description**: Biopharmaceutical company
- **Ownership Structure**: Shares are publicly traded, with ownership distributed among institutional and retail investors
- **Regulatory Classification**: Subject to U.S. Securities and Exchange Commission (SEC) reporting requirements as a public company

## FAQs

**What is Plus Therapeutics?**
Plus Therapeutics is a clinical-stage biopharmaceutical company that develops targeted therapies, primarily for cancer and other life-threatening diseases. It operates as a public company, meaning its shares are available for purchase on the Nasdaq stock exchange.

**What therapies does Plus Therapeutics develop?**
The company focuses on **targeted therapies**, including experimental treatments for brain cancers (e.g., glioblastoma) and other rare or difficult-to-treat conditions. Its pipeline includes drug candidates in various stages of clinical trials.

**How is Plus Therapeutics different from private biotech companies?**
As a **public company**, Plus Therapeutics raises capital by selling shares to the general public via Nasdaq, whereas private biotech firms rely on private investors or venture capital. This structure subjects Plus Therapeutics to stricter regulatory oversight, including quarterly financial disclosures and shareholder transparency requirements.

**What is the significance of its Nasdaq listing?**
The Nasdaq listing (ticker: **PSTV**) allows Plus Therapeutics to access public markets for funding, which can accelerate drug development and commercialization. The **Central Index Key (CIK: 0001095981)** is a unique identifier assigned by the SEC for regulatory filings.

**Who owns Plus Therapeutics?**
Ownership is distributed among **public shareholders**, including institutional investors (e.g., hedge funds, mutual funds) and individual retail investors who purchase shares on Nasdaq. The company’s board of directors oversees governance, elected by shareholders.

**What is the company’s history and origin?**
Plus Therapeutics was founded in **1996** and originally operated under a different name (Cytori Therapeutics) before rebranding. It transitioned to its current focus on targeted therapies, particularly in oncology, and has maintained its public status since at least **2000**.

**What are the risks of investing in Plus Therapeutics?**
As a **clinical-stage biopharmaceutical company**, its drug candidates face high failure rates in clinical trials, which could impact share value. Additionally, as a small-cap public company, its stock may be volatile and subject to market fluctuations.

## Why It Matters
Plus Therapeutics plays a critical role in the **biopharmaceutical ecosystem** by advancing **targeted therapies** for diseases with limited treatment options, such as aggressive brain cancers. As a **public company**, it provides a model for how early-stage drug developers can secure funding from public markets to accelerate research, bridging the gap between academic innovation and commercial viability. Its work contributes to:
- **Patient Impact**: Developing potential treatments for rare and deadly diseases where few options exist.
- **Investor Opportunity**: Offering retail and institutional investors exposure to high-risk, high-reward biotech ventures.
- **Industry Innovation**: Demonstrating the viability of public funding for niche therapeutic areas, particularly in oncology.
- **Regulatory Transparency**: As a Nasdaq-listed company, it adheres to SEC disclosure rules, providing investors with visibility into its financial health and clinical progress.

## Notable For
- **Public Market Access**: One of the few small-cap biopharmaceutical companies listed on Nasdaq, enabling broader investor participation in its growth.
- **Clinical Pipeline**: Focuses on **targeted therapies**, including experimental treatments for **glioblastoma**, a highly aggressive brain cancer with limited approved therapies.
- **Rebranding and Evolution**: Transitioned from its original identity (Cytori Therapeutics) to its current focus, reflecting a strategic pivot in its therapeutic approach.
- **SEC Compliance**: Maintains rigorous reporting standards as a public company, including quarterly (10-Q) and annual (10-K) filings, which enhance investor trust.
- **Crunchbase Recognition**: Listed under the organization ID **cytori-therapeutics**, indicating its historical and operational footprint in the biotech sector.
- **Wikidata Classification**: Formally recognized as a **biopharmaceutical company**, distinguishing it from broader pharmaceutical or medical device firms.

## Body

### History and Evolution
Plus Therapeutics was established in **1996**, initially under a different corporate identity. The company underwent a **rebranding process** to align with its current focus on **targeted therapies**, particularly in oncology. Its origins trace back to earlier ventures in regenerative medicine before pivoting to its present therapeutic areas. The company has maintained its **public status** since at least **2000**, when it began trading on Nasdaq under its current or predecessor ticker symbol.

### Corporate Structure and Governance
As a **public company**, Plus Therapeutics is governed by a **board of directors** elected by shareholders. The board oversees executive leadership, including the CEO and other C-suite officers, who manage day-to-day operations. The company’s **dual-class share structure** (if applicable) or other governance mechanisms may influence voting rights and decision-making processes, though specific details are not provided in the source material.

Key governance features include:
- **Shareholder Meetings**: Annual and special meetings to vote on major corporate actions (e.g., mergers, board elections).
- **SEC Filings**: Mandatory disclosures, including **10-K (annual reports)**, **10-Q (quarterly reports)**, and **8-K (current reports)** for material events.
- **Audit Committee**: Oversees financial reporting and compliance with accounting standards.

### Financial and Market Profile
- **Stock Exchange**: Nasdaq (ticker: **PSTV**)
- **Central Index Key (CIK)**: **0001095981** (unique SEC identifier for filings)
- **Market Capitalization**: As a small-cap biotech company, its market cap fluctuates based on clinical trial outcomes, FDA approvals, and investor sentiment.
- **Revenue Model**: Primarily reliant on **public funding** (via stock sales) and potential partnerships or licensing deals for drug candidates. Unlike large pharmaceutical companies, it may not yet generate significant revenue from commercialized products.

### Therapeutic Focus and Pipeline
Plus Therapeutics specializes in **targeted therapies**, with a pipeline centered on:
- **Oncology**: Experimental treatments for **glioblastoma** and other brain cancers, which are often resistant to conventional therapies.
- **Rare Diseases**: Potential therapies for conditions with unmet medical needs.
- **Clinical Stages**: Drug candidates are likely in **Phase 1 or Phase 2 clinical trials**, though specific details about its pipeline are not provided in the source material.

### Regulatory and Compliance Landscape
As a **public biopharmaceutical company**, Plus Therapeutics operates under multiple regulatory frameworks:
- **SEC Oversight**: Compliance with **Securities Act of 1933** (initial public offerings) and **Securities Exchange Act of 1934** (ongoing reporting).
- **FDA Regulations**: Clinical trials and drug development must adhere to **FDA guidelines**, including **Investigational New Drug (IND)** applications and **New Drug Applications (NDAs)**.
- **Nasdaq Listing Requirements**: Maintenance of minimum share price, market capitalization, and financial reporting standards.

### Headquarters and Operational Base
- **Location**: Austin, Texas, United States
- **Significance**: Austin is a growing hub for **biotech and life sciences**, offering access to talent, research institutions (e.g., University of Texas at Austin), and venture capital. The city’s business-friendly environment may support Plus Therapeutics’ operational and fundraising efforts.

### Investor Profile and Shareholder Base
- **Institutional Investors**: May include hedge funds, mutual funds, or biotech-focused investment firms.
- **Retail Investors**: Individual shareholders who purchase shares via brokerage accounts.
- **Volatility**: As a small-cap biotech stock, **PSTV** may experience significant price swings based on clinical trial results, FDA decisions, or market trends.

### Industry Context and Competitive Landscape
Plus Therapeutics competes in the **oncology and rare disease drug development** space, which includes:
- **Large Pharmaceutical Companies**: e.g., Pfizer, Merck, which have extensive pipelines and commercialized products.
- **Other Small-Cap Biotechs**: Companies with similar market caps and clinical-stage pipelines, often competing for investor attention and partnership deals.
- **Academic and Non-Profit Research**: Collaborations with universities or research institutions may supplement its in-house development efforts.

### Crunchbase and Wikidata Recognition
- **Crunchbase ID**: **cytori-therapeutics** (indicates historical data or predecessor entity).
- **Wikidata Description**: Classified as a **biopharmaceutical company**, distinguishing it from broader categories like "pharmaceutical company" or "medical device manufacturer."

### Challenges and Risks
- **Clinical Trial Failures**: High attrition rates in drug development, particularly for oncology therapies.
- **Funding Dependence**: Reliance on public markets for capital, which may dry up during market downturns or biotech sector sell-offs.
- **Regulatory Hurdles**: FDA approval processes are lengthy and costly, with no guarantee of success.
- **Competition**: Competing with larger, better-funded companies for investor dollars and partnership opportunities.

### Future Outlook
Plus Therapeutics’ trajectory depends on:
- **Clinical Trial Success**: Positive results in its pipeline could drive stock price appreciation and attract partnerships.
- **FDA Approvals**: Regulatory milestones may unlock commercialization opportunities.
- **Strategic Partnerships**: Collaborations with larger pharmaceutical companies could provide funding and expertise.
- **Market Conditions**: Biotech sector trends, interest rates, and investor sentiment will influence its ability to raise capital.